Crinetics Pharmaceuticals grants stock options to new employees under Inducement Plan

From GlobeNewswire: 2024-08-12 16:05:00

Crinetics Pharmaceuticals, Inc. granted 103,900 stock options to new non-executive employees under the 2021 Inducement Plan with an exercise price of $47.64 per share. Options will vest over four years, subject to continued employment (source: Globe Newswire).

Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and tumors, with lead candidate paltusotine in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome. Another candidate, atumelnant, is completing Phase 2 studies for congenital adrenal hyperplasia and Cushing’s disease. The company’s drug candidates are orally delivered small molecules for various endocrine conditions (source: Globe Newswire).

For investor relations, contact Gayathri Diwakar at [email protected] or (858) 345-6340. For media inquiries, contact Natalie Badillo at [email protected] or (858) 450-6464 (source: Globe Newswire).



Read more at GlobeNewswire: Crinetics Pharmaceuticals Announces August 2024 Inducement